Age, Biography and Wiki
Michelle Dipp was born on 1976, is an American scientist, businesswoman and investor. Discover Michelle Dipp's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is she in this year and how she spends money? Also learn how she earned most of networth at the age of 48 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
48 years old |
| Zodiac Sign |
N/A |
| Born |
|
| Birthday |
|
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on .
She is a member of famous Businesswoman with the age 48 years old group.
Michelle Dipp Height, Weight & Measurements
At 48 years old, Michelle Dipp height not available right now. We will update Michelle Dipp's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Who Is Michelle Dipp's Husband?
Her husband is Bill Detwiler (2021–current)
| Family |
| Parents |
Not Available |
| Husband |
Bill Detwiler (2021–current) |
| Sibling |
Not Available |
| Children |
Not Available |
Michelle Dipp Net Worth
Her net worth has been growing significantly in 2023-2024. So, how much is Michelle Dipp worth at the age of 48 years old? Michelle Dipp’s income source is mostly from being a successful Businesswoman. She is from . We have estimated Michelle Dipp's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
Businesswoman |
Michelle Dipp Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
Michelle Dipp is an American scientist, businesswoman, and investor.
She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.
Michelle Dipp was raised in El Paso, Texas.
Her mother was a nurse in the ER and her father was a businessman.
Dipp attended Loretto Academy, where she graduated in 1994.
She graduated with a bachelor's degree, an M.D., and a Ph.D. in physiology from Oxford University.
After graduation, Dipp moved to Boston, Massachusetts.
In 2005, she began working at Sirtris Pharmaceuticals, a startup that created drugs that were meant to slow aging and protect against degenerative diseases related to aging.
The company researched and tested activators of sirtuin, such as resveratrol formulations.
In 2008, she became vice president of corporate development at Sirtris Pharmaceuticals.
Sirtris was purchased and made a subsidiary of GlaxoSmithKline in 2008.
At GlaxoSmithKline, Dipp became the head of their Center of Excellence for External Drug Discovery.
In 2008, Dipp worked with Christoph Westphal, Richard Aldrich, and Alexey Margolin to found Alnara Pharmaceuticals, which was created to develop ways to formulate biopharmaceuticals so they could be taken by mouth, instead of by injection.
In February 2010, Dipp, Westphal, and Aldrich formed a new venture fund called Longwood Founders Fund.
In August 2010, the Longwood team co-founded VeraStem by providing seed funding and office space its offices; Verastem aimed to isolate cancer stem cells and then discover drugs that would selectively kill them.
The company held its IPO in 2012.
In January 2015 Longwood and Dipp helped found Flex Pharma
In November 2016 Dipp and Longwood helped launch Axial Biotherapeutics where she took a board seat.
In October 2017 Dipp became the Managing Director at General Atlantic, a global growth equity firm based in New York City.
Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee while at General Atlantic.
Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.
In 2020, Dipp founded Biospring Partners with Jennifer Lum to conduct venture capital in the life sciences industry.
Investments for Biospring Partners include funding for Abzena who were subsequently selected to work on the antibody cocktail for COVID 19 treatment.
On June 30, 2020, the Securities and Exchange Commission announced that Michelle Dipp, a co-founder and former CEO of the now defunct OvaScience, Inc., agreed to settle fraud charges for misleading investors about the availability and commercial prospects for the company’s fertility treatments that were in development.
